A detailed history of Crossmark Global Holdings, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 185,326 shares of BMY stock, worth $10.7 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
185,326
Previous 345,405 46.35%
Holding current value
$10.7 Million
Previous $14.3 Million 33.15%
% of portfolio
0.17%
Previous 0.27%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$39.66 - $51.75 $6.35 Million - $8.28 Million
-160,079 Reduced 46.35%
185,326 $9.59 Million
Q2 2024

Jul 29, 2024

BUY
$40.25 - $52.99 $1.11 Million - $1.46 Million
27,509 Added 8.65%
345,405 $14.3 Million
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $1.28 Million - $1.45 Million
26,696 Added 9.17%
317,896 $17.2 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $2.44 Million - $2.92 Million
50,406 Added 20.93%
291,200 $14.9 Million
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $482,976 - $540,042
-8,343 Reduced 3.35%
240,794 $13.6 Million
Q2 2023

Jul 31, 2023

BUY
$63.71 - $70.74 $1.42 Million - $1.58 Million
22,291 Added 9.83%
249,137 $15.3 Million
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $803,304 - $911,129
12,225 Added 5.7%
226,846 $15.7 Million
Q4 2022

Jan 19, 2023

BUY
$68.48 - $81.09 $7.98 Million - $9.46 Million
116,603 Added 118.96%
214,621 $15.4 Million
Q3 2022

Nov 01, 2022

BUY
$0.13 - $76.84 $5,869 - $3.47 Million
45,153 Added 85.41%
98,018 $6.97 Million
Q2 2022

Jul 29, 2022

BUY
$72.62 - $79.98 $429,547 - $473,081
5,915 Added 12.6%
52,865 $4.07 Million
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $164,028 - $196,684
-2,668 Reduced 5.38%
46,950 $3.43 Million
Q4 2021

Jan 10, 2022

BUY
$53.63 - $62.52 $15,552 - $18,130
290 Added 0.59%
49,618 $3.09 Million
Q3 2021

Oct 21, 2021

BUY
$59.17 - $69.31 $2.41 Million - $2.82 Million
40,688 Added 470.93%
49,328 $2.92 Million
Q3 2021

Oct 13, 2021

SELL
$59.17 - $69.31 $2.46 Million - $2.88 Million
-41,539 Reduced 82.78%
8,640 $292,000
Q2 2021

Jul 21, 2021

SELL
$61.91 - $67.42 $374,926 - $408,295
-6,056 Reduced 10.77%
50,179 $3.35 Million
Q1 2021

Apr 15, 2021

BUY
$59.34 - $66.74 $72,276 - $81,289
1,218 Added 2.21%
56,235 $3.55 Million
Q4 2020

Jan 14, 2021

SELL
$57.74 - $65.43 $2,771 - $3,140
-48 Reduced 0.09%
55,017 $3.41 Million
Q3 2020

Oct 08, 2020

SELL
$57.43 - $63.64 $106,934 - $118,497
-1,862 Reduced 3.27%
55,065 $3.32 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $265,438 - $310,323
4,842 Added 9.3%
56,927 $3.35 Million
Q1 2020

Apr 28, 2020

BUY
$46.4 - $67.43 $88,484 - $128,589
1,907 Added 3.8%
52,085 $2.9 Million
Q4 2019

Feb 06, 2020

BUY
$49.21 - $64.19 $928,199 - $1.21 Million
18,862 Added 60.23%
50,178 $3.22 Million
Q3 2019

Oct 09, 2019

SELL
$42.77 - $50.71 $288,269 - $341,785
-6,740 Reduced 17.71%
31,316 $1.59 Million
Q2 2019

Jul 09, 2019

SELL
$44.62 - $49.34 $9,191 - $10,164
-206 Reduced 0.54%
38,056 $1.73 Million
Q1 2019

May 02, 2019

SELL
$45.12 - $53.8 $70,161 - $83,659
-1,555 Reduced 3.91%
38,262 $1.83 Million
Q4 2018

Jan 31, 2019

BUY
$48.76 - $63.23 $61,437 - $79,669
1,260 Added 3.27%
39,817 $2.07 Million
Q3 2018

Nov 08, 2018

BUY
$55.19 - $62.25 $191,509 - $216,007
3,470 Added 9.89%
38,557 $2.39 Million
Q2 2018

Jul 31, 2018

SELL
$50.53 - $62.98 $311,770 - $388,586
-6,170 Reduced 14.96%
35,087 $1.94 Million
Q1 2018

Apr 16, 2018

SELL
$59.92 - $68.98 $145,725 - $167,759
-2,432 Reduced 5.57%
41,257 $2.61 Million
Q4 2017

Feb 05, 2018

BUY
$59.94 - $65.35 $41,478 - $45,222
692 Added 1.61%
43,689 $2.68 Million
Q3 2016

Oct 25, 2017

BUY
N/A
42,997
42,997 $2.74 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Crossmark Global Holdings, Inc. Portfolio

Follow Crossmark Global Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.